The Munich-based biotech SaaS start-up knowing01 GmbH has successfully completed an oversubscribed six-figure pre-seed financing round. Led by Backbone Ventures and supported by renowned business angels from the DACH region, including Dr. Julia Ju, Veronika Chrestin, Björn W. Schäfer and Johannes Stiber, this financing enables knowing01 to accelerate the development of its AI-based software for contextualizing molecular data and thus reduce risks in the early phase of drug development.
knowing01 is in a unique position at the intersection of deep tech, biotech and SaaS. By combining advanced AI with the power of biomedical data, the company is transforming the way researchers gain insights from complex data sets. With a fast, easy-to-use software solution, pharma and biotech companies will be able to make smarter decisions based on biomedical data and reduce the costs and risks of drug development in a way that cannot be achieved with traditional methods.
Last year, the company successfully launched its first product on the European biotech market. The new funding will be used to further expand the software's capabilities, accelerate commercial activities in the biotech and pharmaceutical sectors and grow the team. In 2015, the start-up was a successful m4 Award winner.
Knowing01's proprietary AI-powered multiomics platform enables researchers to gain insights from existing data with a scalable in silico approach to achieve better research results with fewer errors. Multiomics refers to the integration of different biological data types, such as genomics, proteomics and transcriptomics, to gain a comprehensive overview of biological processes.
“With our solution, we enable scientists to leverage unused data sources and make more profound decisions in drug development,” says Dr. Nikola Müller, founder and CEO of knowing01.
Backbone Ventures, a German-Swiss VC firm, led the pre-seed financing round via its 5502 Fund.